Alto Neuroscience, Inc. (ANRO)
$22.09-8.53%Close
SELLCRISIS · day 15
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $775M
- Beta
- 1.16
- P/E (TTM)
- -8.91
- Short % float
- 13.26%
- Days to cover
- 6.5
- SI change
- +11.7%
- 1W
- -6.75%
- 1M
- -30.27%
- vs SPY 1W
- -6.62%
- vs SPY 1M
- -32.78%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 18
- VALUE
- 7
- GROWTH
- 47
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-27.9%
REV YoY-
ROE-46.5%
EPS YoY-
ROA-33.2%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-8.91
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B4.31
P/FCF-
EV/EBITDA-6.63
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E3.22
ALTMAN Z-
CURR RATIO14.85
ND/EBITDA-
BETA1.16
Company news
FAQ
- What is LOPJLB’s current signal on ANRO?
- LOPJLB’s latest quantitative signal on Alto Neuroscience, Inc. (ANRO) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ANRO in?
- Alto Neuroscience, Inc. (ANRO) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Alto Neuroscience, Inc. (ANRO) do?
- Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as…